Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07135687 · ClinicalTrials.gov registry record · Phase 4
Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction
A Phase 4 study, sponsored by Rush University Medical Center.
- Not yet
- Registry status
- Phase 4
- Development phase
- 144
- Enrollment target
NCT07135687 is a Phase 4 study that has not yet begun recruiting, run by Rush University Medical Center. The registered enrollment target is 144 participants.
The verdict
NCT07135687, a Phase 4 study, has not yet begun recruiting, sponsored by Rush University Medical Center.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 144 participants
- Enrollment target
Study Summary
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Interventions
- OTHER Placebo
- DRUG Losartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 144 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07135687
The ClinicalTrials.gov registry entry for NCT07135687 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 144 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rush University Medical Center, which has 320 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07135687 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07135687 about?
NCT07135687 is a clinical study titled "Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction". The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair ...
What is the current status of trial NCT07135687?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 144 participants. The study started on 2026-08. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07135687?
The interventions under investigation include: Placebo (OTHER), Losartan (DRUG).
Who is sponsoring clinical trial NCT07135687?
This trial is sponsored by Rush University Medical Center, which has 320 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.